OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
Sharad Verma, Sukriti Goyal, Anchala Kumari, et al.
PLoS ONE (2018) Vol. 13, Iss. 2, pp. e0190942-e0190942
Open Access | Times Cited: 8
Sharad Verma, Sukriti Goyal, Anchala Kumari, et al.
PLoS ONE (2018) Vol. 13, Iss. 2, pp. e0190942-e0190942
Open Access | Times Cited: 8
Showing 8 citing articles:
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
Regina Padmanabhan, Hadeel Kheraldine, Nader Meskin, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 636-636
Open Access | Times Cited: 54
Regina Padmanabhan, Hadeel Kheraldine, Nader Meskin, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 636-636
Open Access | Times Cited: 54
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
María Gaibar, Laura Beltrán, Alicia Romero‐Lorca, et al.
Journal of Oncology (2020) Vol. 2020, pp. 1-13
Open Access | Times Cited: 52
María Gaibar, Laura Beltrán, Alicia Romero‐Lorca, et al.
Journal of Oncology (2020) Vol. 2020, pp. 1-13
Open Access | Times Cited: 52
Precision medicine review: rare driver mutations and their biophysical classification
Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, et al.
Biophysical Reviews (2019) Vol. 11, Iss. 1, pp. 5-19
Open Access | Times Cited: 53
Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, et al.
Biophysical Reviews (2019) Vol. 11, Iss. 1, pp. 5-19
Open Access | Times Cited: 53
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
Md. Sazzad Hassan, Fiona Williams, Niranjan Awasthi, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 21
Md. Sazzad Hassan, Fiona Williams, Niranjan Awasthi, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 21
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Alvan Cai, Yuan Chen, Lily S. Wang, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2635-2635
Open Access | Times Cited: 2
Alvan Cai, Yuan Chen, Lily S. Wang, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2635-2635
Open Access | Times Cited: 2
Computational investigation of phytochemicals identified from medicinal plant extracts against tuberculosis
Nirmaladevi Ponnusamy, G.S. Pillai, Mohanapriya Arumugam
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 7, pp. 3382-3395
Closed Access | Times Cited: 5
Nirmaladevi Ponnusamy, G.S. Pillai, Mohanapriya Arumugam
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 7, pp. 3382-3395
Closed Access | Times Cited: 5
Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs
M. Ayub, A Tyagi, Sunil K. Srivastava, et al.
Journal of Materials Chemistry B (2024) Vol. 13, Iss. 1, pp. 218-238
Closed Access | Times Cited: 1
M. Ayub, A Tyagi, Sunil K. Srivastava, et al.
Journal of Materials Chemistry B (2024) Vol. 13, Iss. 1, pp. 218-238
Closed Access | Times Cited: 1
Network biology of lapatinib resistance in different types of HER2-positive breast cancers informs the prioritization of the combination anticancer treatments as anti-resistance interventions
Bayan Alkhawaja, Anas Khaleel, Wael Abu Dayyih, et al.
F1000Research (2023) Vol. 12, pp. 256-256
Open Access
Bayan Alkhawaja, Anas Khaleel, Wael Abu Dayyih, et al.
F1000Research (2023) Vol. 12, pp. 256-256
Open Access
